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ABSTRACT 
 
Background 
Venous thromboembolism (VTE) is a common and potentially life threatening disease. 
Women have different risk factors than men at both first and recurrent VTE. The aim of 
this thesis was to further identify and explore risk factors for VTE in young and middle 
aged women.   
 
Methods 
A nationwide case-control study of genetic and environmental risk factors for VTE in 
women aged 18-64 years was conducted in Sweden 2001-2009. The study was called 
Thrombo Embolism Hormone Study (TEHS) and comprised 1377 cases and 1402 age 
matched controls. In a sub study called hypo-TEHS, 244 of the cases included in the 
TEHS-study were followed up with plasma samples and questionnaires after cessation 
of anticoagulant therapy. Levels of coagulation factors and thrombin generation was 
measured and compared between obese and non obese patients.  The women were also 
followed up at least 24 months after the diagnosis of VTE to assess data on recurrence. 
We investigated if there was any correlation between the levels of thrombin generation, 
resistance to activated protein C (APC) and increased risk of recurrent events. To assess 
the influence of other risk factors for recurrent VTE, all cases included in TEHS were 
followed up after four years in the TEHS-follow-up study.  
 
Results 
Data from the TEHS study presented in this thesis showed that family history of VTE 
was predictive of increased risk of hormone, surgery and cast related VTE in women. In 
the hypo-TEHS study we found that obese women with VTE had increased levels of 
thrombin generation with two different laboratory methods, compared to the non obese 
women with VTE. Obesity was also related to higher inflammatory markers such as 
CRP and fibrinogen. Furthermore we found that increased thrombin generation was 
associated to increased risk of recurrent VTE, as was APC-resistance in the absence of 
the factor V Leiden mutation. In the TEHS follow-up study the risk of recurrence in 
women was found to be only 2 %. When the risk of recurrence in patients with hormone 
related first thrombosis was evaluated we found it to be higher than in surgery provoked 
first event but lower than in women with unprovoked first thrombosis.  
 
Conclusions 
The most important risk factors for VTE in young and middle aged women are use of 
hormones, surgery and cast. Assessment of family history of venous thrombosis could 
help to better identify women at increased risk prior to hormonal treatment or decision 
on prophylaxis after surgery/ cast. Obesity is another important risk factor for both first 
and recurrent VTE.  Obese female VTE patients had higher thrombin generation than 
non obese patients which could represent one mechanism of how obesity is related to 
the increased risk of recurrent VTE. In the clinical situation, the overall risk of 
recurrence in VTE must be weight against the risk of bleeding complications on 
anticoagulant therapy. Data from the hypo-TEHS study showed that women with APC-
resistance in the absence of Factor V Leiden are at increased risk of recurrence. In the 
TEHS follow-up we fund the overall risk of recurrent VTE to be lower than the 
expected risk of bleeding complications. Integration of gender and knowledge on the 
specific risk factors in women when estimating the risk of recurrence could improve the 
care of VTE patients. 
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